Navigation auf uzh.ch
Navigation auf uzh.ch
In a significant step towards fostering international collaboration in the field of regenerative medicine, the Center for iPS Cell Research and Application (CiRA) at Kyoto University recently hosted seven researchers (Beatriz Achón Buil,Vanessa Budny, Arian Ehterami, Carmen Helfensteiner, Nora Rentsch, David Taborsky, and Dennis Zorndt) and their mentor Dr. Melanie Generali from the Institute for Regenerative Medicine (IREM), University of Zurich (UZH) for a 21-day research exchange.
This exchange, which took place from October 21 to November 10, provided a unique opportunity for UZH scientists to engage in cutting-edge research on induced pluripotent stem (iPS) cells, a technology poised to revolutionize regenerative medicine.
The participants were assigned to various CiRA laboratories that align with their individual research themes. They were given the opportunity to immerse themselves in advanced lab techniques, including iPS cell culture, differentiation, and experimental protocols. Alongside their hands-on training, the students benefited from close mentorship and collaborative discussions with CiRA’s world-renowned researchers.
This exchange program is part of an ongoing partnership between IREM and CiRA, which has been strengthening ties since 2017. The collaboration is aimed at advancing joint research and facilitating the transfer of technology between Switzerland and Japan. It also offers a valuable platform for cultural exchange, fostering a deeper understanding between the two institutions and enhancing the global network of regenerative medicine researchers.
During their stay, the researchers not only participated in laboratory work but also engaged in interdisciplinary discussions during a joint symposium that broadened their perspectives on the scientific, ethical, and societal implications of iPS cell research. The experience was not just about advancing their academic knowledge but also about building lasting international relationships that will contribute to the development of the next generation of regenerative medicine therapies.
For CiRA and IREM, this exchange marks another milestone in a fruitful and dynamic partnership that continues to drive innovation and progress in the rapidly advancing field of regenerative medicine. The visit is expected to strengthen future collaborative efforts, furthering the development of life-changing therapies based on iPS cell technology.
As the global scientific community continues to come together to address some of the most pressing challenges in medicine, exchanges like this demonstrate the power of international cooperation in fostering innovation and training the next generation of leaders in the field of regenerative medicine.
Melanie Generali
